Zika Virus

4
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
3100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Moderna
ModernaCAMBRIDGE, MA
3 programs
2
1
mRNA-1893Phase 2RNA Therapeutic1 trial
mRNA-1325Phase 1RNA Therapeutic1 trial
mRNA-1893Phase 1RNA Therapeutic1 trial
Active Trials
NCT03014089Completed90Est. Jul 2019
NCT04064905Completed120Est. Mar 2021
NCT04917861Completed808Est. Jul 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Single dose of rZIKV/D4Δ30-713Phase 11 trial
Active Trials
NCT03611946CompletedEst. Mar 2022
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
ZIKAlliance Natural History StudyN/A1 trial
ZIKAlliance Pregnant Women CohortN/A1 trial
Active Trials
NCT03204409Withdrawn0Est. Sep 2021
NCT03188731Completed3,852Est. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ModernamRNA-1893
ModernamRNA-1893
Allergy TherapeuticsSingle dose of rZIKV/D4Δ30-713
ModernamRNA-1325
Heidelberg PharmaZIKAlliance Natural History Study
Heidelberg PharmaZIKAlliance Pregnant Women Cohort

Clinical Trials (6)

Total enrollment: 4,870 patients across 6 trials

NCT04917861ModernamRNA-1893

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Start: Jun 2021Est. completion: Jul 2024808 patients
Phase 2Completed
NCT04064905ModernamRNA-1893

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Start: Jul 2019Est. completion: Mar 2021120 patients
Phase 1Completed
NCT03611946Allergy TherapeuticsSingle dose of rZIKV/D4Δ30-713

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

Start: Jul 2018Est. completion: Mar 2022
Phase 1Completed
NCT03014089ModernamRNA-1325

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Start: Dec 2016Est. completion: Jul 201990 patients
Phase 1Completed
NCT03204409Heidelberg PharmaZIKAlliance Natural History Study

ZIKAlliance Natural History Study

Start: Apr 2018Est. completion: Sep 20210
N/AWithdrawn
NCT03188731Heidelberg PharmaZIKAlliance Pregnant Women Cohort

ZIKAlliance Pregnant Women Cohort

Start: May 2017Est. completion: Sep 20213,852 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space